Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2024, Singular Genomics Systems has a Sloan Ratio of 4.50%, indicating the company is in the safe zone and there is no funny business with accruals.
Singular Genomics Systems Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Singular Genomics Systems's Sloan Ratio %
For the Medical Instruments & Supplies subindustry, Singular Genomics Systems's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Singular Genomics Systems's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Singular Genomics Systems's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Singular Genomics Systems's Sloan Ratio % falls into.
Singular Genomics Systems Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Singular Genomics Systems's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Singular Genomics Systems's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -25.578 (Jun. 2023 ) + -22.36 (Sep. 2023 ) + -23.249 (Dec. 2023 ) + -25.024 (Mar. 2024 ) = $-96.21 Mil.
Singular Genomics Systems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -19.998 (Jun. 2023 ) + -16.813 (Sep. 2023 ) + -18.902 (Dec. 2023 ) + -23.703 (Mar. 2024 ) = $-79.42 Mil.
Singular Genomics Systems's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -35.086 (Jun. 2023 ) + -24.703 (Sep. 2023 ) + 0.651 (Dec. 2023 ) + 31.579 (Mar. 2024 ) = $-27.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Singular Genomics Systems (NAS:OMIC) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Singular Genomics Systems has a Sloan Ratio of 4.50%, indicating the company is in the safe zone and there is no funny business with accruals.
Singular Genomics Systems Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Singular Genomics Systems's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Singular Genomics Systems (Singular Genomics Systems) Business Description
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OMIC has been successfully added to your 